ライフサイエンスコーパス: peripheral arterial disease

1 rization, angina, stroke, heart failure, and peripheral arterial disease).

2 riables (C) (smoking, diabetes mellitus, and peripheral arterial disease).

3 tection of disease and monitoring therapy in peripheral arterial disease.

4 ients with stable coronary artery disease or peripheral arterial disease.

5 tients, women, and patients with diabetes or peripheral arterial disease.

6 ld yield the most efficacious treatments for peripheral arterial disease.

7 t-reported walking performance developed for peripheral arterial disease.

8 t disease (CHD), cerebrovascular disease and peripheral arterial disease.

9 in ischemia-induced angiogenesis, such as in peripheral arterial disease.

10 bility could be extended to patients without peripheral arterial disease.

11 ther the WIQ can be used in patients without peripheral arterial disease.

12 ith diabetes, tobacco use, heart failure, or peripheral arterial disease.

13 lar morbidity and mortality in patients with peripheral arterial disease.

14 ent-resistant hypertension, preeclampsia, or peripheral arterial disease.

15 oke, nephropathy, ischemic heart disease and peripheral arterial disease.

16 t limb salvage rates in patients with severe peripheral arterial disease.

17 ial femoral artery of diabetic patients with peripheral arterial disease.

18 tudied and validated therapy for symptomatic peripheral arterial disease.

19 art disease, coronary revascularisation, and peripheral arterial disease.

20 ative to PTA for treatment of infrapopliteal peripheral arterial disease.

21 ry heart disease, heart failure, stroke, and peripheral arterial disease.

22 heart disease, cerebrovascular disease, and peripheral arterial disease.

23 schaemic heart disease, ischaemic stroke, or peripheral arterial disease.

24 with less functional decline in persons with peripheral arterial disease.

25 th less functional decline among people with peripheral arterial disease.

26 ations for clinical imaging in patients with peripheral arterial disease.

27 aemorrhage, carotid dissection, and, rarely, peripheral arterial disease.

28 onal decline in persons with lower-extremity peripheral arterial disease.

29 ans taking care of patients with symptomatic peripheral arterial disease.

30 , and depression worsens vascular outcome in peripheral arterial disease.

31 ponses are impaired in elderly patients with peripheral arterial disease.

32 utive patients underwent PER for symptomatic peripheral arterial disease.

33 schemia, such as coronary artery disease and peripheral arterial disease.

34 ed as coronary heart disease, stroke, and/or peripheral arterial disease.

35 CVD included CHD, stroke, heart failure, and peripheral arterial disease.

36 diseases such as coronary artery disease and peripheral arterial disease.

37 ) is a widely utilized measure for detecting peripheral arterial disease.

38 o 2.69 for stroke, and from 1.66 to 4.28 for peripheral arterial disease.

39 ovascular and surgical revascularization for peripheral arterial disease.

40 o 1.53 for stroke, and from 0.61 to 1.58 for peripheral arterial disease.

41 chemia is a life-threatening complication of peripheral arterial disease.

42 interventions in patients with asymptomatic peripheral arterial disease.

43 f progression of kidney disease, stroke, and peripheral arterial disease.

44 ischemic heart disease, ischemic stroke, and peripheral arterial disease.

45 patients with chronic coronary syndromes or peripheral arterial disease.

46 al limb ischemia represents the end stage of peripheral arterial disease.

47 reperfuse the limbs of certain patients with peripheral arterial disease.

48 s (46% of possible matches), 95% of whom had peripheral arterial disease.

49 s in patients with stable coronary artery or peripheral arterial disease.

50 ipheral blood flow in selected patients with peripheral arterial diseases.

51 g 0.91 [95% CI 0.86-0.98]) and strongest for peripheral arterial disease (1.23 [1.20-1.27]).

52 dial infarction, 1.78 (95% CI 1.53-2.07) for peripheral arterial disease, 1.32 (95% CI 1.15-1.50) for

53 presentation, of which the most common were peripheral arterial disease (16.2%, n=992) and heart fai

54 e patients with stent occlusion or stenoses, peripheral arterial disease (ABI <1.0), symptomatic card

55 etes was strongly positively associated with peripheral arterial disease (adjusted cause-specific haz

56 pe 2 diabetes was positively associated with peripheral arterial disease (adjusted HR 2.98 [95% CI 2.

57 ovascular disease mortality and one study on peripheral arterial disease).All but one study reported

58 ion of serum selenium with the prevalence of peripheral arterial disease among 2,062 US men and women

59 herapeutic values for the pathophysiology of peripheral arterial disease and cancer.

60 xtremity arterial intima of individuals with peripheral arterial disease and diabetes.

61 l CVD events (coronary, cerebrovascular, and peripheral arterial disease and heart failure).

62 ng is critical for blood flow restoration in peripheral arterial disease and is triggered by increasi

63 Ischemia (CLI) is the most advanced stage of peripheral arterial disease and is usually treated with

64 ociation between this noninvasive measure of peripheral arterial disease and mortality risk.

65 ncreased in a range of conditions, including peripheral arterial disease and myocardial infarction, w

66 in the response to ischemia associated with peripheral arterial disease and myocardial infarction.

67 l arterial disease, the use of paclitaxel in peripheral arterial disease and other conditions, the ha

68 er peripheral arterial revascularization for peripheral arterial disease and to assess whether readmi

69 VD, defined as coronary, cerebrovascular, or peripheral arterial disease, and (2) incident heart fail

70 0.722 for ADA HbA1c clinical categories for peripheral arterial disease, and 0.683 for ADA fasting g

71 l duration, the absence of beta-blocker use, peripheral arterial disease, and a deeper prosthesis ins

72 rt failure with preserved ejection fraction, peripheral arterial disease, and abdominal aortic aneury

73 nary heart disease, cerebrovascular disease, peripheral arterial disease, and all-cause cardiovascula

74 onic kidney disease, cardiovascular disease, peripheral arterial disease, and all-cause mortality tha

75 are performed in patients with diabetes and peripheral arterial disease, and at least 25% require su

76 r disease, including coronary heart disease, peripheral arterial disease, and cerebrovascular disease

77 Hypertension, myocardial infarction, peripheral arterial disease, and impaired renal function

78 CAC] scores, carotid intima-media thickness, peripheral arterial disease, and pulse wave velocity).

79 ith reduced risks of coronary heart disease, peripheral arterial disease, and stroke.

80 eria included diabetes mellitus, symptomatic peripheral arterial disease, and superficial femoral art

81 hypertension, previous heart failure, MI, or peripheral arterial disease; and who received coronary a

82 patients more often had a history of stroke, peripheral arterial disease, angina, heart failure, diab

83 eart failure after myocardial infarction and peripheral arterial disease are predominant, devastating

84 Heart failure and peripheral arterial disease are the most common initial

85 options for the treatment of lower extremity peripheral arterial disease are typified with diminished

86 ional decline in people with lower extremity peripheral arterial disease are unknown.

87 ongly associated with coronary, cerebral and peripheral arterial disease, as well as with microangiop

88 CLI is an advanced form of peripheral arterial disease associated with nonhealing a

89 roke, coronary heart disease, heart failure, peripheral arterial disease, asthma, chronic kidney dise

90 roke, coronary heart disease, heart failure, peripheral arterial disease, asthma, chronic kidney dise

91 erosclerosis (ie, risk factors, coronary and peripheral arterial disease, asymptomatic carotid stenos

92 r the treatment of patients with symptomatic peripheral arterial disease because they are associated

93 Rates of evaluation for peripheral arterial disease before amputation were low,

94 rization, angina, stroke, heart failure, and peripheral arterial disease), but less effective in prev

95 e and blood flow in an experimental model of peripheral arterial disease, by exploiting fluorescence

96 The fully adjusted odds ratios for peripheral arterial disease comparing selenium quartiles

97 cular (cerebrovascular, coronary artery, and peripheral arterial diseases) complications.

98 ction, pre-procedural myocardial infarction, peripheral arterial disease, congestive heart disease, r

99 ary artery disease, cerebrovascular disease, peripheral arterial disease, congestive heart failure, m

100 Further they had more peripheral arterial disease, coronary artery disease, ca

101 y of autologous cell therapy for intractable peripheral arterial disease/critical limb ischemia.

102 age-, sex-, and race-adjusted prevalence of peripheral arterial disease decreased with increasing se

103 rd quantitative imaging approach to evaluate peripheral arterial disease does not exist.

104 r, rheumatic heart disease, aortic aneurysm, peripheral arterial disease, endocarditis, and all other

105 Peripheral arterial disease epidemiology and/or manageme

106 monary disease, acute myocardial infarction, peripheral arterial disease, epilepsy, substance abuse,

107 ace, renal disease, diabetes mellitus, known peripheral arterial disease, evaluation by a vascular sp

108 disease, 117 cerebrovascular disease, and 98 peripheral arterial disease events.

109 1 years) and 13 patients suspected of having peripheral arterial disease (five men; mean age, 67 year

110 vascular disease (coronary artery disease or peripheral arterial disease) followed from 1997 to 2009,

111 Isner, the field of cell-based therapies for peripheral arterial disease has been in a state of conti

112 shed CV disease, including HTN, HF, CHD, and peripheral arterial disease, have a better prognosis com

113 1.5-2.0) for stable angina, ischemic stroke, peripheral arterial disease, heart failure, and cardiac

114 risk factors include advanced age, smoking, peripheral arterial disease, high blood pressure, corona

115 tio [HR], 0.77; 95% CI, 0.62-0.94; P = .01), peripheral arterial disease (HR, 0.65; 95% CI, 0.49-0.87

116 se (HR, 0.82), heart failure (HR, 0.84), and peripheral arterial disease (HR, 0.85).

117 hiectomy was noted for fractures (HR, 1.80), peripheral arterial disease (HR, 2.25), venous thromboem

118 95% confidence interval [CI]: 1.82 to 2.29), peripheral arterial disease (HR: 1.95; 95% CI: 1.72 to 2

119 myocardial infarction (HR=1.75, P=0.02), and peripheral arterial disease (HR=2.01, P=0.01).

120 pulmonary disease, coronary artery disease, peripheral arterial disease, hypertension, pulmonary hyp

121 ischemia may contribute to worse outcomes of peripheral arterial disease in patients with diabetes me

122 The age-adjusted prevalence of peripheral arterial disease in the US population has bee

123 The age-adjusted prevalence of peripheral arterial disease in the US population was est

124 open AAA repair, bypass for lower extremity peripheral arterial disease - in Ontario, Canada, betwee

125 Surgical treatment options for peripheral arterial disease include angioplasty, endarte

126 The clinical consequences of occlusive peripheral arterial disease include intermittent claudic

127 The clinical consequences of occlusive peripheral arterial disease include pain on walking (cla

128 The prevalence of peripheral arterial disease increases with the age of th

129 hospitalization, cardiac revascularization, peripheral arterial disease intervention, or cardiovascu

130 Peripheral arterial disease is a common disease that has

131 Peripheral arterial disease is a major complication of d

132 Peripheral arterial disease is a manifestation of system

133 Peripheral arterial disease is associated with adverse c

134 Peripheral arterial disease is largely considered to be

135 Because peripheral arterial disease is most commonly caused by a

136 Peripheral arterial disease is one manifestation of syst

137 pulation ages, the overall population having peripheral arterial disease is predicted to rise.

138 taneous interventions for lifestyle-limiting peripheral arterial disease is unknown.

139 self as acute coronary syndrome, stroke, and peripheral arterial diseases, is a chronic progressive i

140 worsen the prognosis of myocardial ischemia, peripheral arterial disease, ischemic stroke, etc.

141 cerebrovascular accident, heart failure, and peripheral arterial disease), kidney disease (a composit

142 We hypothesized that in peripheral arterial disease, maladaptive changes in VEGF

143 Treatment of peripheral arterial diseases may be distinguished into c

144 For peripheral arterial disease, men with PLMI >/=30 compare

145 thesis in conditions that simulate tumor and peripheral arterial disease microenvironment.

146 In a mouse hindlimb ischemia model of peripheral arterial disease, MITCH-PEG co-delivery of hi

147 pes) (effective sample size [n(e)] = 9,396); peripheral arterial disease (n(e) = 5,215); abdominal ao

148 40,258; cerebrovascular disease, n = 18,843; peripheral arterial disease, n = 8273) or 3 or more risk

149 (Comprehensive Magnetic Resonance of Peripheral Arterial Disease; NCT00587678).

150 ferumoxytol-enhanced MR angiography revealed peripheral arterial disease not recognized with duplex U

151 ce interval [CI], 0.31-0.45; P=5.5*10(-26)], peripheral arterial disease (odds ratio 0.42; 95% CI, 0.

152 ression analysis revealed that patients with peripheral arterial disease of the lower extremities are

153 Patients with peripheral arterial disease often undergo peripheral end

154 artery disease, cerebrovascular disease, or peripheral arterial disease or with multiple risk factor

155 hrombotic (coronary, cerebrovascular, and/or peripheral arterial) disease or multiple atherothromboti

156 pertension (OR, 0.58; 95% CI, 0.43-0.78) and peripheral arterial disease (OR, 0.43; 95% CI, 0.22-0.85

157 a-blocker use (OR, 0.12; 95% CI, 0.03-0.45), peripheral arterial disease (OR, 6.36; 95% CI, 1.56-25.8

158 ificant associations between the CAD-GRS and peripheral arterial disease (OR: 1.28; 95% CI: 1.23 to 1

159 levels but without coronary artery disease, peripheral arterial disease, or diabetes mellitus.

160 option for patients with renal dysfunction, peripheral arterial disease, or following a brief P2Y12-

161 e patients with prior myocardial infarction, peripheral arterial disease, or stroke.

162 Patients with diabetes, heart failure, peripheral arterial disease, or tobacco use had the larg

163 rtality, including among individuals without peripheral arterial disease (P<0.001).

164 diabetes (P<0.0001), hypertension (P<0.001), peripheral arterial disease (P=0.0002), smoking (P<0.000

165 ves (adjusted chi-square=38.3, p <0.001) and peripheral arterial disease (PAD) (adjusted chi-square=1

166 Peripheral arterial disease (PAD) affects 5 million peop

167 ardiovascular disease (CVD) risk factors and peripheral arterial disease (PAD) after adjustment for t

168 risk factors explain the high prevalence of peripheral arterial disease (PAD) among African American

169 2 diabetes respond poorly to treatments for peripheral arterial disease (PAD) and are more likely to

170 lthough exertional leg pain is a hallmark of peripheral arterial disease (PAD) and can occur in perso

171 els, inorganic arsenic exposure is linked to peripheral arterial disease (PAD) and cardiovascular dis

172 eadmill walking performance in patients with peripheral arterial disease (PAD) and intermittent claud

173 o determine differences in the prevalence of peripheral arterial disease (PAD) and its associations w

174 ent study were to describe the prevalence of peripheral arterial disease (PAD) and its effects on pro

175 Peripheral arterial disease (PAD) and osteoporosis are c

176 The ABI is used to diagnose peripheral arterial disease (PAD) and to identify those

177 rs that regulate angiogenesis are altered in peripheral arterial disease (PAD) and whether these fact

178 m a vascular cohort with a history of either peripheral arterial disease (PAD) and/or other cardiovas

179 Patients with peripheral arterial disease (PAD) are at a high risk for

180 Patients with peripheral arterial disease (PAD) are at increased risk

181 Data on the natural history of peripheral arterial disease (PAD) are scarce and are foc

182 aimed to investigate the pathophysiology of peripheral arterial disease (PAD) by examining magnetic

183 Peripheral arterial disease (PAD) caused by occlusive at

184 Peripheral arterial disease (PAD) causes significant mor

185 HF), myocardial infarction (MI), stroke, and peripheral arterial disease (PAD) during the subsequent

186 Importance: Patients with concomitant peripheral arterial disease (PAD) experience worse cardi

187 Patients with peripheral arterial disease (PAD) have high rates of adv

188 Men and women with lower extremity peripheral arterial disease (PAD) have higher levels of

189 Patients with peripheral arterial disease (PAD) have increased risk on

190 ain the higher prevalence of lower-extremity peripheral arterial disease (PAD) in black adults.

191 vious studies have indicated higher rates of peripheral arterial disease (PAD) in blacks than in non-

192 Cadmium has been associated with peripheral arterial disease (PAD) in cross-sectional stu

193 only used bedside tests for the detection of peripheral arterial disease (PAD) in diabetes.

194 Homocysteine levels are associated with peripheral arterial disease (PAD) in observational studi

195 index (BMI; weight (kg)/height (m)(2)) with peripheral arterial disease (PAD) in prior studies may r

196 scular reactivity and functional capacity in peripheral arterial disease (PAD) in small, short-term s

197 europathy, chronic kidney disease (CKD), and peripheral arterial disease (PAD) in the general populat

198 Peripheral arterial disease (PAD) is a chronic, lifestyl

199 Peripheral arterial disease (PAD) is a clinical conditio

200 Peripheral arterial disease (PAD) is a clinical manifest

201 Peripheral arterial disease (PAD) is a costly source of

202 Peripheral arterial disease (PAD) is a subclinical measu

203 Peripheral arterial disease (PAD) is an important cardio

204 Lower-extremity peripheral arterial disease (PAD) is associated with dec

205 Peripheral arterial disease (PAD) is caused by atheroscl

206 Peripheral arterial disease (PAD) is common but commonly

207 The prevalence of peripheral arterial disease (PAD) is increasing worldwid

208 It was hypothesized that peripheral arterial disease (PAD) is less frequent after

209 iovascular disease, but its association with peripheral arterial disease (PAD) is unclear.

210 PURPOSE OF REVIEW: Peripheral arterial disease (PAD) is underdiagnosed, und

211 le of inflammation in the pathophysiology of peripheral arterial disease (PAD) is well established, t

212 ides an advantageous approach to symptomatic peripheral arterial disease (PAD) over the longer term.

213 in patients with and without lower-extremity peripheral arterial disease (PAD) over three-year follow

214 etics plays an important role in determining peripheral arterial disease (PAD) pathology, which cause

215 I] 1.0 +/- 0.1, mean age 30 +/- 7 years); 2) peripheral arterial disease (PAD) patients (n = 12; mean

216 gnetic resonance spectroscopy in symptomatic peripheral arterial disease (PAD) patients compared with

217 in gastrocnemius biopsies from patients with peripheral arterial disease (PAD) predict mortality rate

218 Genetic determinants of peripheral arterial disease (PAD) remain largely unknown

219 rmining the amputation risk in patients with peripheral arterial disease (PAD) remains difficult.

220 STF) recently released an update to its 1996 Peripheral Arterial Disease (PAD) Screening Recommendati

221 CKD) substantially increases the severity of peripheral arterial disease (PAD) symptomology, however,

222 Peripheral arterial disease (PAD) was defined by ankle b

223 blood and urine cadmium concentrations with peripheral arterial disease (PAD) were evaluated by usin

224 rmined whether patients with lower-extremity peripheral arterial disease (PAD) who are more physicall

225 the association of progressive versus stable peripheral arterial disease (PAD) with the risk of futur

226 cise nor strength training for patients with peripheral arterial disease (PAD) without intermittent c

227 hypothesized that women with lower extremity peripheral arterial disease (PAD) would have greater mob

228 ABI categories were defined: <0.90 (definite peripheral arterial disease (PAD)), 0.90-0.99 (borderlin

229 l nervous system, but their association with peripheral arterial disease (PAD), a high-prevalence vas

230 CRP (P< or =0.05) and increasing severity of peripheral arterial disease (PAD), after adjustment for

231 sessed plasma-based factors as predictors of peripheral arterial disease (PAD), and comparative data

232 Among individuals with lower-extremity peripheral arterial disease (PAD), specific leg symptoms

233 Several risk factors for atherosclerotic peripheral arterial disease (PAD), such as dyslipidemia,

234 the management of patients with established peripheral arterial disease (PAD), the prevalence of PAD

235 In participants with peripheral arterial disease (PAD), we determined whether

236 R angiography for suspected or known chronic peripheral arterial disease (PAD), with contrast materia

237 ar events and amputation among patients with peripheral arterial disease (PAD).

238 is frequently performed for the treatment of peripheral arterial disease (PAD).

239 al ankle-brachial index (ABI) and those with peripheral arterial disease (PAD).

240 higher mortality rates in men and women with peripheral arterial disease (PAD).

241 ct cardiovascular mortality in patients with peripheral arterial disease (PAD).

242 atherosclerosis in patients with concomitant peripheral arterial disease (PAD).

243 uscle perfusion in subjects with progressive peripheral arterial disease (PAD).

244 The 666 participants included 412 with peripheral arterial disease (PAD).

245 quality of life in asymptomatic persons with peripheral arterial disease (PAD).

246 rction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD).

247 mes in a cohort of patients with symptomatic peripheral arterial disease (PAD).

248 alf strength in persons with lower extremity peripheral arterial disease (PAD).

249 ility loss among persons with versus without peripheral arterial disease (PAD).

250 ing ischemia to lower limbs in patients with peripheral arterial disease (PAD).

251 des a promising avenue for the management of peripheral arterial disease (PAD).

252 the reference standard for the diagnosis of peripheral arterial disease (PAD).

253 promote physiological angiogenesis to treat peripheral arterial diseases (PAD) by increasing the vas

254 The impact of polyvascular disease (peripheral arterial disease [PAD] and cerebrovascular di

255 ETHODS AND The study population included 203 peripheral arterial disease participants who underwent v

256 Peripheral arterial disease patients included those with

257 2 improves treadmill exercise performance in peripheral arterial disease patients with claudication-l

258 rticularly important for the large number of peripheral arterial disease persons without access to su

259 oronary artery disease, limb ischemia due to peripheral arterial disease, pressure-overload heart fai

260 In spline regression models, peripheral arterial disease prevalence decreased with in

261 Peripheral arterial disease prevalence ranged from 3.1%

262 orbidities including hypertension, diabetes, peripheral arterial disease, previous myocardial infarct

263 e, diabetes mellitus, hypertension, smoking, peripheral arterial disease, previous stroke, previous c

264 s without clinical CVD but with asymptomatic peripheral arterial disease, regardless of its low CVD r

265 3 US Medicare patients who underwent a major peripheral arterial disease-related amputation during th

266 nding on vascular care and regional rates of peripheral arterial disease-related amputation.

267 ulmonary disease, calcified ascending aorta, peripheral arterial disease, renal failure, and previous

268 presentation, the most common of which were peripheral arterial disease (reported in 992 [16.2%] of

269 Peripheral Arterial Disease Research Coalition (Europe).

270 Atherosclerosis in the form of peripheral arterial disease results in significant morbi

271 myocardium, atrial fibrillation, aortic and peripheral arterial disease, rheumatic heart disease, an

272 at interventions to prevent mobility loss in peripheral arterial disease should focus on reversing pa

273 roke, chronic obstructive pulmonary disease, peripheral arterial disease, smoking, diabetes, renal fa

274 pecificity, 96%; LR, 3.1 [95% CI, 2.0-4.7]), peripheral arterial disease (specificity, 97%; LR, 2.7 [

275 usion in "no-option" patients suffering from peripheral arterial diseases, such as critical limb isch

276 tients with prior coronary artery disease or peripheral arterial disease the COMPASS (Cardiovascular

277 ional, and surgical therapy for coronary and peripheral arterial disease, the burden of these illness

278 eaders Forum reviewed the natural history of peripheral arterial disease, the use of paclitaxel in pe

279 are recommended for secondary prevention in peripheral arterial disease, their effectiveness in CLI

280 a risk equivalent condition for coronary and peripheral arterial diseases, these findings create a pa

281 ion procedures is increased in patients with peripheral arterial disease, thus increasing the inciden

282 f myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg

283 AND Three hundred seventy participants with peripheral arterial disease underwent baseline measureme

284 Any fractures, peripheral arterial disease, venous thromboembolism, car

285 Peripheral arterial disease was defined as an ankle brac

286 Peripheral arterial disease was defined as an ankle-brac

287 Hospitalization for peripheral arterial disease was infrequent, with annuali

288 serum selenium levels and the prevalence of peripheral arterial disease was not statistically signif

289 icenter study, 141 patients with symptomatic peripheral arterial disease were assigned to treatment w

290 na, recent coronary artery bypass graft, and peripheral arterial disease were associated with prescri

291 , chronic obstructive pulmonary disease, and peripheral arterial disease were less likely to improve

292 ntrolled trial, 76 patients with symptomatic peripheral arterial disease were randomized 2:1 to recei

293 left ventricular ejection fraction <20%, and peripheral arterial disease were significant predictors

294 Treatment options for diabetic patients with peripheral arterial disease when revascularization is no

295 effect on angina, myocardial infarction, and peripheral arterial disease, whereas raised diastolic bl

296 igger of chronic coronary, intracranial, and peripheral arterial diseases, which together account for

297 unweighted hospitalizations of patients with peripheral arterial disease who had peripheral arterial

298 More than 1 in 6 patients with peripheral arterial disease who undergo peripheral arter

299 andomized trial in symptomatic patients with peripheral arterial disease who underwent endovascular t

300 ong 61 969 hospitalizations of patients with peripheral arterial disease who were discharged alive af